Regeneron Pharmaceuticals, Inc. · NASDAQ:REGN
Regeneron Pharmaceuticals — Investor Presentation (July 2026)
34 slides from Regeneron Pharmaceuticals's investor presentation, July 2026
Slide 1: Regeneron Corporate Presentation
Regeneron Corporate Presentation J U L Y 2 0 2 6 This non-promotional presentation contains investigational data as well as forward-looking statements; actual results may vary materially.
Slide 2: Note regarding forward-looking statements and non-GAAP financial measures
Note regarding forward-looking statements and non-GAAP financial measures This presentation includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual even
Slide 3: Leveraging the power of science to bring transformative medicines to patients
Integrating Genetics, Accelerating Following Delivering Proteomics, and Innovation and Breakthrough Big Data R&D Productivity the Science Medicines World’s largest DNA and Powerful toolkit of ~50 clinical programs across 15 internally-developed proteomics-linked healthcare proprietary, turnkey techn
Slide 4: Q2 2026 Financial Performance and Pipeline Developments
Q2 2026 Financial Notable R&D Pipeline Advancements Performance and Pipeline Developments • Approved in U.S. and Europe for pediatric chronic spontaneous urticaria (age 2 -11 yrs) • FDA approved extended dosing intervals (every-20-week dosing regimen) in wAMD and DME Other Products and Programs • FD
Slide 5: Dupixent: >1.5 million patients on therapy globally
Continued growth and expansion in multiple Type 2 indications Q2 2026 Dupixent global net sales of $6B (+38% YoY*) >1.5 million patients on therapy globally Dupixent global net product sales, in $ Millions Q2 2026 net product sales increased 38% YoY* +38%* Approved in NINE indications globally, most
Slide 6: Strong launches in new indications while unlocking revenue growth through development balance repayment
Strong launches in new indications while unlocking revenue growth through development balance repayment New launches and repayment of development balance driving Sanofi Collaboration Revenue growth in 2026 Dupixent Cumulative NBRx by Indication Reimbursement Obligation to Sanofi Weekly launch-aligne
Slide 7: EYLEA HD + EYLEA in the U.S.
EYLEA HD + EYLEA in the U.S. EYLEA HD + EYLEA remain the U.S. branded anti-VEGF category leader U.S. Net Product Sales, in $ Millions Goal to establish EYLEA HD as new standard of care for retinal diseases • Q2 2026 U.S. net product sales of $596M $754 $681 $577 $412 • Comprised ~60% of Q2 2026 aggr
Slide 8: Strengthening EYLEA HD's best-in-class profile
Strengthening EYLEA HD’s best-in-class profile Recent label enhancements broadening adoption to patients with RVO and to patients requiring more frequent dosing Macula Edema following Maximized Dosing Flexibility Retinal Vein Occlusion (RVO) • Offers physicians greater flexibility to • EYLEA HD ever
Slide 9: Driving global Oncology growth through differentiated launches
Driving global Oncology growth through differentiated launches Positive early launch progress with Libtayo in adjuvant CSCC and Lynozyfic in r/r multiple myeloma Engaging with a broader range Libtayo is the only NCCN 10,000+ eligible patients Adjuvant CSCC of treating specialties Category 1 Preferre
Slide 10: Key growth driver and foundational to oncology portfolio
Key growth driver and foundational to oncology portfolio Building on leadership in non-melanoma skin cancers with adjuvant CSCC launch; growing share in advanced non small cell lung cancer Strong and consistent growth Libtayo global net product sales, • Q2 2026 global net sales of $489M (+29% YoY*)
Slide 11: Lynozyfic provides a differentiated clinical profile in the BCMA bispecific class
R/R Multiple Myeloma: Lynozyfic provides a differentiated and compelling clinical profile in the BCMA bispecific class There are no randomized, head-to-head clinical trials between these products. Study data being provided for descriptive purposes only. Caution is advised when drawing conclusions ba
Slide 12: Regeneron pipeline targets large opportunities across therapeutic categories
Regeneron pipeline targets large opportunities across therapeutic categories Immunology & Inflammation IL-13 Type 2 Indications Ophthalmology IL-4 Type 2 Indications Oncology & Heme-Onc IL-4xIL-13 bispecific§ Type 2 Indications Lynozyfic (BCMAxCD3) Multiple myeloma Cemdisiran (C5 siRNA) ± freneslerb
Slide 13: Sustaining I&I leadership and unlocking new growth opportunities
Sustaining I&I leadership and unlocking new growth opportunities Leveraging learnings from Dupixent and disease biology to advance next-gen approaches to treat inflammatory diseases Pursuing multi-pronged approach to sustain Advancing broader allergy pipeline I&I leadership into the next decade into
Slide 14: Key late-stage programs positioned to deliver over the next few years
Key late-stage programs positioned to deliver over the next few years Late-stage opportunities spanning multiple therapeutic areas CEMDISIRAN ± CENVACIBART & OLATOREPATIDE (OLA) POZELIMAB AMRECIBART ± VARIOUS AGENTS BCMAxCD3 C5 siRNA ± C5 antibody Two Factor XI antibodies allow GIP/GLP-1, combinatio
Slide 15: Lynozyfic strategy and long-term vision
Lynozyfic strategy and long-term vision Unlocking long-term value by redefining multiple myeloma treatment and prevention Establish Advance Prevent • Build market share in late-line • Move to earlier lines of • Differentiated strategy to myeloma through positive treatment with differentiated, addres
Slide 16: Aiming to transform the multiple myeloma treatment landscape
Aiming to transform the multiple myeloma treatment landscape Registrational program underway to potentially transform the treatment paradigm with convenient, simplified and less intense treatment regimens At Lynozyfic 200 mg monotherapy, 100% of evaluable patients (n=21) achieved MRD-negativity in H
Slide 17: Comprehensive development plan across disease spectrum
Comprehensive development plan across disease spectrum Numerous pivotal studies ongoing, with multiple readouts expected through 2027–2030 to support paradigm-shifting potential and a significant commercial opportunity Indication/ Target Monotherapy Dose MRD-negativity Setting Study Name Phase Enrol
Slide 18: Differentiated therapeutic approaches to complement-mediated diseases
Differentiated therapeutic approaches to complement-mediated diseases driven by the underlying disease biology Gastroenterology Hematology Neurology Ophthalmology CHAPLE Paroxysmal Nocturnal Generalized Myasthenia Geographic Disease Hemoglobinuria (PNH) Gravis (gMG) Atrophy (GA) U.S. Prevalence <100
Slide 19: Significant commercial opportunity across multiple complement-mediated diseases
Significant commercial opportunity across multiple complement-mediated diseases Cemdisiran Monotherapy We believe late-stage, differentiated C5 Myasthenia Gravis program with near-term launches across U.S. Launch expected Q4 2026 multiple indications creates meaningful 2025 U.S. Prevalence (patients
Slide 20: Cemdisiran's differentiated clinical profile for gMG
Cemdisiran’s differentiated clinical profile offers potential advantages to currently approved advanced therapies for gMG Cemdisiran’s potential clinical differentiation MG-ADL Total Score • Potential first-in-class siRNA treatment for gMG, offering a novel mechanism of action for this disease Novel
Slide 21: Tailored approach to anticoagulation with differentiated Factor XI program
Tailored approach to anticoagulation treatment with differentiated Factor XI program Regeneron’s two antibodies allow customized approach: Cenvacibart optimizes anticoagulation activity with potential for reduced bleeding risk vs. SOC, Amrecibart further reduces bleeding risk with comparable anticoa
Slide 22: Regeneron's broad Factor XI clinical program
Addressing the bleeding risk in anticoagulation treatment: Regeneron’s broad Factor XI clinical program $20B anticoagulation market remains underpenetrated due to bleeding risk; <50% of eligible patients receive therapy because of safety concerns Stroke Post-TKR Cancer PICC-associated Peripheral Pre
Slide 23: Broad Factor XI development program advancing rapidly
Broad Factor XI development program advancing rapidly Genetics, preclinical, and clinical data support broad Factor XI development Target Treatment Est. Est. Primary Patient Segment Study Enrollment Period Study Start Completion ROXI-APEX Post-Total Knee Replacement (Cat vs. apixaban vs. ~2,000 Sing
Slide 24: Transforming patient care for obesity and related conditions
Transforming patient care for obesity and related conditions Three major opportunities for Regeneron in the rapidly growing obesity therapeutic area 1 2 3 Address obesity GIP/GLP-1 Receptor Enhancing the quality of comorbidities with novel Agonist monotherapy GLP-1-based weight loss combinations Imp
Slide 25: World-class Regeneron Genetic Medicines (RGM) Program
Alnylam: Exclusive siRNA World-class Regeneron Genetic Medicines collaboration in eye and CNS, with liver programs in MASH (RGM) Program and additional RGC targets RGM builds and utilizes ‘turnkey’ therapeutic platforms — customizing In-House: Developing next- the choice of genetics technology (siRN
Slide 26: Regeneron Genetic Medicines Pipeline
Regeneron Genetic Medicines Pipeline Phase 1 Phase 2 Phase 3 ALN-5288* ALN-SNCA* ALN-HTT02* ALN-PNP* Rapirosiran* ALN-SOD* Cemdisiran ± Pozelimab* Gene Silencing (siRNA) MAPT (Tau) siRNA SNCA (synuclein) HTT siRNA PNPLA3 siRNA HSD17B13 SOD1 siRNA C5 siRNA ± C5 antibody Neuro-degenerative siRNA Hu t
Slide 27: Approved and investigational medicines across a diverse set of diseases
Regeneron approved and investigational medicines across a diverse set of diseases Phase 1 Phase 2 Phase 3 FDA-Approved † REGN5837 (CD22xCD28) ubamatamab (MUC16xCD3) odronextamab (CD20xCD3) ° REGN7945 (CD38xCD28) nezastomig (PSMAxCD28) linvoseltamab (BCMAxCD3) REGN17372 (GPRC5DxCD28) marlotamig (EGFR
Slide 28: 2026 anticipated key milestones
2026 anticipated key milestones Ophthalmology Hematology • EYLEA HD: pre-filled syringe FDA decision • R7508/R9933: Initiate additional Phase 3 studies in anticoagulation • Cemdisiran ± pozelimab: report interim results from lead in (2H26) cohort of Phase 3 trial in GA (4Q26) • Cemdisiran + Pozelima
Slide 29: Deploying capital to maximize long-term value creation
Deploying capital to maximize long-term value creation Disciplined capital allocation approach laying the foundation for Regeneron’s next wave of innovation Return Capital to Shareholders Business Development Investing in world-class Leveraging external Rewarding shareholders Internal Investment R&D
Slide 30: Our responsibility strategic framework sets a clear path to a healthier world
Our responsibility strategic framework sets a clear path to a healthier world Applying our unique knowledge and expertise to address the issues that matter most to our business and stakeholders SCIENCE Innovating to deliver groundbreaking medicines ACCESS Advancing access to medicine for patients PE
Slide 31: Science-led 2030 goals
16 SCIENCE-LED 2030 GOALS WILL HOLD US ACCOUNTABLE TO PROGRESS AND REAL-WORLD IMPACT SCIENCE ACCESS PEOPLE PLANET Apply REGN innovation to deliver Advance access to medicine for Fuel the pipeline of future scientific Protect ecosystems essential to human groundbreaking medicines by: patients by: inn
Slide 32: Our 2025 progress at a glance
Our 2025 progress at a glance Approximately Industry Ratings and Rankings5 50 >83K eligible1 patients provided ~$2.8B2 worth of medicine at no cost through product candidates in ut p u t ’ p t t t p g clinical development S&PGlobal Corporate Top 4% Sustainability 50% Announced that we will donate up
Slide 33: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations 33
Slide 34: Abbreviations and Definitions
Abbreviations and Definitions Abbreviation Definition Abbreviation Definition Abbreviation Definition Abbreviation Definition 1L First line DOAC Direct oral anticoagulants Low-Density Lipoprotein / PI Prescribing information LDL/LDL-C 2L Second line EC European Commission Low-Density Lipoprotein-Cho
Regeneron Pharmaceuticals — Investor Presentation (July 2026) on 6ix